natgillin/translations-raw huggingface dataset:
The antibody for use of claim 15, wherein said cancer is a solid tumor selected from the group consisting of a head & neck tumor, a brain tumor, an esophageal tumor, a breast tumor, a lung tumor, a liver tumor, a spleen tumor, a stomach tumor, a small intestinal tumor, a large intestinal tumor, a rectal tumor, an ovarian tumor, a uterine tumor, a cervical tumor, a prostate tumor, a testicular tumor and a skin tumor, or wherein said cancer is a blood cancer selected from the group consisting of leukemia and lymphoma. 
Antitijelo za upotrebu prema zahtjevu 15, pri čemu spomenuti rak je čvrsti tumor odabran iz grupe koja se sastoji iz tumora glave & vrata, tumora mozga, tumora jednjaka, tumora grudi, tumora pluća, tumora jetre, tumora slezene, tumora želuca, tumora tankog crijeva, tumora debelog crijeva, tumora rektuma, tumora jajnika, tumora maternice, cervikalnog tumora, tumora prostate, tumora testisa i tumora kože, ili gdje je spomenuti rak rak krvi izabran iz grupe koja obuhvaća leukemiju i limfom.
Progesterone for use in the treatment of traumatic brain injury in a human subject, said treatment comprising administering to said human subject a therapeutically effective amount of progesterone by means of intravenous infusion to achieve a final progesterone serum level of about 100 ng/ml to about 1000 ng/ml. 
Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dvorazinski intravenski režim doziranja progesterona resultira razinom progesterona u serumu kod navedenog subjekta od otprilike 100 ng/ml do otprilike 2000 ng/ml.
reacting 2-fluorobenzenesulfonyl chloride, and tetra-n-butylammonium fluoride to provide 2-fluorobenzenesulfonyl fluoride and isolating or not isolating the 2-fluorobenzenesulfonyl fluoride; 
HR P20130635 T1 (m) reagiranja 2-fluorobenzensulfonil klorida, i prvog izvora fluorida kako bi se dobio 2-fluorobenzensulfonil
The device according to claim 1, further comprising a bias power supply that is coupled to the power supply circuit and that is operable to generate a bias voltage for the overvoltage monitor circuit. The device according to claim 1, wherein the bi-directional voltage limiter comprises: 
Uređaj (10, 10A, 10B) prema zahtjevu 1, naznačen time da nadalje sadrži kompenzacijsko napajanje (200) koje je spojeno na krug napajanja i koje radi tako da generira kompenzacijski napon za krug nadzora prenapona (210, 220).
The crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione of claim 16, wherein the further X-ray powder diffraction peaks are at 17.6, 20.6, 24.1 and 26.0 degrees 2θ. 
Kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion u skladu s patentnim zahtjevom 16, naznačen time što su daljnji pikovi difrakcije rendgenskih zraka na prahu na 17,6, 20,6, 24,1 i 26,0 stupnjeva 2θ.
A solution of 7.04 g (32.9 mmol) of NaIO4 in 110 mL of water was added very slowly, drop by drop, and then stirred for 1 hour at room temperature. 
Polako, kap po kap, doda se otopinu od 7,04 g (32,9 mmola) NalOy u 110 mL vode i zatim se miješa 1 sat pri sobnoj temperaturi.
fermenting a stream of unsorted MSW in a microbial fermentation reactor in which the unsorted MSW is fermented with an inoculated microbial consortium and with agitation at a non-water content of between 10 and 50% by weight and at a temperature of between 35 and 75 degrees C. for a period of between 1 and 72 hours, under conditions sufficient to maintain a live lactic acid bacteria concentration of at least 1.0×1010 CFU/L, wherein said microbial consortium comprises live lactic acid bacteria and wherein said microbial consortium provides a microbially-derived cellulase activity of at least 30 Filter Paper Units/Liter (FPU/L), and wherein said unsorted MSW comprises a mixture of biogenic and non-biogenic material in which 15% by weight or greater of the dry weight is non-biogenic material, and removing a stream of fermented unsorted MSW from the reactor and subjecting it to a separation step whereby non-biodegradable solids are removed to provide a slurry of bio-degradable components. 
Postupak obrade krutog komunalnog otpada (MSW), naznačen time što se sastoji u koracima – dodavanja struje nesortiranog MSW u reaktor za mikrobnu fermentaciju u kojem se MSW fermentira uz miješanje, uz sadržaj nevodenih tvari koji se kreće između 10 i 50 %, težinski, te na temperaturi koja se kreće između 35 i 75 °C, u trajanju između 1 i 72 sati, u uvjetima dovoljnim za održavanje koncentracije živih mliječnokiselinskih bakterija od najmanje 1,0 x 1010 CFU/l, gdje se mikrobnu celulaznu aktivnost od najmanje 30 FPU/l postiže mikrobnim konzorcijem koji omogućuje mikrobnu fermentaciju, i – uklanjanja struje fermentiranog nesortiranog MSW iz reaktora i njegovog podvrgavanja koraku odvajanja, gdje se nerazgradljive krutine uklanja kako bi se dobilo mulj od biorazgradljivih komponenata.
the electronic logic and display section or card (4) comprises means adapted to indicate both algebraically and graphically the variations of the resistance encountered by the tool during the operating phases, means adapted to parameterize the variations of the resistance and means adapted to visualize the variations of the resistance in the form of an average value, a peak value and integral value expressed in Newton/cm. 
što elektronička sekcija logike i displeja ili elektronička kartica logike i displeja obuhvaća sredstvo koje je tako prilagođeno da pokazuje, kako algebarski tako i grafički, varijacije otpora, koji otpor se javlja na alatu za vrijeme radnih faza, zatim obuhvaća sredstvo koje je tako prilagođeno da određuje parametre varijacija otpora i sredstvo koje je prilagođeno tako da vizualizira varijacije otpora u obliku srednje vrijednosti, vršne vrijednosti i integralne vrijednosti koje su izražene u Newton/cm.
The container assembly according to claim 5, wherein the cover comprises a protective cap for covering the membrane. 
Sklop (300) posude prema Zahtevu 5, gdje pokrivač (2) sadrži zaštitni poklopac za pokrivanje membrane (28).
Drying the trousers. Manufacturing method, according to claim 15, characterized in that the addition of polyurethane and polyethylene is made before the drying step of the second phase. 
Postupak proizvodnje, u skladu s patentnim zahtjevom 15, naznačen time, da je dodavanje poliuretana i polietilena napravljeno prije koraka sušenja u drugoj fazi.
printing the marking thereon using an ink of the conventional type; applying a thermochromic ink, which is coloured below the temperature, but becomes colourless when the predetermined temperature is reached or exceeded, so that the marking is substantially invisible below the predetermined temperature, but becomes visible when the predetermined temperature is reached or exceeded. 
Cc) nanošenje termokromne tiskarske boje koja ima obojenje ispod spomenute predodređene temperature, ali postaje bezbojna kada se dosegne ili premaši spomenuta predodređena temperatura, tako da navedena oznaka (12') postaje uglavnom nevidljiva ispod spomenute predodređene temperature, no opet postaje vidljiva kada se dosegne ili premaši spomenuta predodređena temperatura, naznačen time, da se navedena termokromna tiskarska boja nanosi tako, da stvara sloj (12") koji je smješten granično pored navedene oznake (12).
The different salts of the compound may exist in the form of solvates, i.e. 
Različite soli predmetnog spoja mogu postojati u obliku solvata, tj.
at least one of said assays is configured as a competitive binding assay, and wherein said one or more assays optionally comprise assays that detect Coagulation factor VII, and optionally one, two or more of CA19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13. 
najmanje jedno od navedenih ispitivanja je podešeno kao ispitivanje na kompetitivno vezanje, i gdje navedeno jedno ili više ispitivanja može uključivati ispitivanja kojima se detektira protein 7 koji veže inzulinu sličan čimbenik rasta.
Statin drugs are currently the most therapeutically effective drugs available for reducing the level of LDL in the blood stream of a patient at risk for cardiovascular disease. 
Statini su trenutno terapijski najučinkovitiji lijekovi dostupni za smanjenje razine LDL-a u krvotoku pacijenata s rizikom od kardiovaskularnih bolesti.
The corresponding bonding areas may have the form of short stripes, wherein the stripes may be horizontally arranged or may also be inclined with respect to circumferential direction. 
Navedena područja spajanja mogu imati oblik kratkih traka, pri čemu ove trake mogu biti postavljene ili mogu također biti skošene u odnosu na obodni smjer.
Long Term Assay Stability of Alkaloid (nicotine) containing Lozenges with Phosphate Buffer stored at 25° C./60% RH. 
Dugotrajni test stabilnosti tablete koje sadrže alkaloid (nikotin) sa fosfatnim puferom Čuvane na 25%C/60% relativne vlažnosti
Preferably, the linker L' is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane; and/or, m is 1 and L is a carboxamido oligoethylene glycol, preferably a carboxamido triethylene glycol; and/or C is selected from the group consisting of single or double chain fatty acids, folates and cholesterol. 
(Ile), gdje se podcrtani nukleotid odnosi na nukleotid koji ima ili koji nema fosforotioatnu ili metilfosfonatnu okosnicu, vezani L' se bira iz skupine koju čine heksaetilen-glikol, tetradeoksitimidilat (T4) 1 2,19-bis(fosfor)-8-hidraza-1- hidroksi-4-oksa-9-oksononadekan; m je 1, L je karboksamidooligoetilen-glikol, a C se bira iz skupine koju čine dioleo1l, oktadecil, folna kiselina, tokoferol i kolesterol.
At least one compound of Formula (I) or Formula (II) in accordance to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for use in combination with an additional therapeutic agent which include antiemetic agents, anti-inflammatory agents, immunomodulatory agents, cytokines, antidepressants, hormones, alkylating agents, antimetabolites, antitumour antibiotics, antimitotic agents, topoisomerase inhibitors, cytostatic agents, anti-invasion agents, antiangiogenic agents, inhibitors of growth factor function, anticancer agents and toll-like receptor modulators. 
Najmanje jedan spoj s Formulom (I) ili Formulom (II) prema bilo kojem od zahtjeva 1 do 24, ili njegova farmaceutski prihvatljiva sol, naznačen time, što je za uporabu u kombinaciji s drugim terapeutskim sredstvom koje obuhvaća antiemetike, protuupalna sredstva, imunomodulacijska sredstva, citokine, antidepresive, hormone, alkilirajuća sredstva, antimetabolite, antitumorske antibiotike, antimitotička sredstva, inhibitore topoizomeraze, citostatička sredstva, anti-invazivna sredstva, antiangiogena sredstva, inhibitore funkcije čimbenika rasta, antikancerogena sredstva i modulatore toll-u sličnih receptora.
said rotating shaft (5) is received in the through receptacle of the rotating support (3) while creating a form fit therewith with mating sections and 
- - ta rotirajuća osovina (5) ulazi u prolaz okretne potpore (3) pri čemu njihovi oblici međusobno odgovaraju i zahvaćaju se.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačena/e time, da se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa.
A compound selected from the group consisting of: 
Spoj izabran iz skupine koja se sastoji od: nd
polar, unchanged amino acids and/or basic amino acids, or 
između polarnih, nenabijenih aminokiselina i/ili bazičnih aminokiselina, ili
The eluted fractions were evaporated under vacuum, dissolved several times in methanol and evaporated again under vacuum to an oil (0.99 g.). 
Eluirane frakcije se ispare u vakuumu, otope se nekoliko puta u metanolu i ponovno se ispare u vakuumu do ulja (0.99 g.).
Lactose monohydrate, microcrystalline cellulose, the active ingredient, the hydroxypropyl methyl cellulose and half of the croscarmellose sodium were screened into a 10 Litre Fielder high-shear blender (any suitable high shear blender could be used) and blended for 5 minutes at 300 rpm with the chopper off. 
Laktoza monohidrat, mikrokristalna celuloza, aktivni sastojak, hidroksipropil metil celuloza i polovica kroskarameloza natrija se prosiju u 10-litrenu Fielder miješalicu s visokim smicanjem (može se upotrijebiti bilo koja prikladna miješalica s visokim smicanjem) i miješaju 5 minuta pri 300 okr/min s isključenim vibratorom.
Micro-cracks give rise to a degradation of the mechanical properties of the composite material. 
Mikro-naprsnuća mogu povećati oštećenje mehaničkih svojstava materijala.
following contacting said acid(s) with said GNCC, at least one water-soluble salt, which in the case of a hydrogen-containing salt has a pKa of greater than 7, when measured at 20°C, associated with the ionisation of the first available hydrogen, and the salt anion of which is capable of forming water-insoluble calcium salts, is additionally provided; 
poslije kontakta navedene kiseline ili navedenih kiselina sa navedenim GNCC, dodatno je osigurana barem jedna sol topiva u vodi, koja u slučaju soli koja sadrži vodik ima pKa veći od 7, mjereno kod 20°C, povezano sa ionizacijom prvog dostupnog vodika, te anion soli koji je sposoban formirati kalcijeve soli netopive u vodi.
said pH buffering agent is 10 mM histidine and the pH is 5.0; said bulking agent is 2.5% w/v mannitol; and said stabilizing agent is 3.5% w/v sucrose; or 
navedeni pH puferski agens je 10 mM histidin i što je pH 5.0; navedeno sredstvo za dopunjavanje je 2.5% w/v manitol i navedeni stabilizator je 3.5 % w/v saharoza; ili
An antibody that specifically binds human CSF-1R (SEQ ID NO. 
Protutijelo koje se specifično veže na ljudski CSF-IR (SEQ ID NO.
In the second step, the isolation of 7-ethyl-10-hydroxycamptothecin, consists in removal of the solvent mixture by distillation, dilution with water, extraction with chloroform and drying the chloroform layer over magnesium sulfate, followed by purification on a silica gel column with the aim to remove impurities arising in the UV irradiation. 
U drugom koraku 7-etil-10-hidroksikamptotecin se izdvaja uklanjanjem smjese otapala destilacijom, razrjeđivanjem vodom, ekstrakcijom kloroformom, zatim sušenjem kloroformskog sloja preko magnezijevog sulfata, te pročišćavanjem na stupcu silikagela kako bi se uklonilo nečistoće nastale zbog ozračivanja UV zračenjem.
In an opened state of the extraction module the jaw members are distanced from each other while in the closed state the jaw members tightly enclose a capsule space. 
U otvorenom položaju modula za ekstrakciju elementi čeljusti su razmaknuti jedan od drugoga, dok u zatvorenom položaju elementi čeljusti čvrsto obuhvaćaju prostor za čahuru.
Disclosed are CCR1 receptor antagonists of the formula (I) 
Spoj, naznačen time, da ima formulu (I)
wood shavings obtained from pine or fir wood, said shavings have sizes within a range from 1-50 mm; 
• piljevinu dobivenu od bora ili jelovine, navedena piljevina bivajući veličine u rasponu od 1 – 50 mm, poželjno 5 – 20 mm;
Headset apparatus according to any preceding claim in which an aforesaid earshell is arranged to be worn against the head of a user to cover an ear of the user. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da je navedena školjka za uho namještena za nošenje uz glavu korisnika tako, da pokrije uho korisnika.
A solenoid operated valve assembly comprising: 
Sklop elektromagnetskog ventila, koji sadrži:
The process according to claims 7 or 8 wherein the organic solvent is selected form methanol, toluene, xylene, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, isopropyl acetate, ethyl formiate, methyl tertbutyl ether, diethylcarbonate, chlorobenzene, dichloromethane and mixtures thereof. 
Postupak u skladu s patentni zahtjevi 7 ili 8, naznačen time što se organsko otapalo bira između metanola, toluena, ksilena, acetona, etil-acetata, acetonitrila, tetrahidrofurana, izopropil-acetata, etil-formijata, metil-tert-butil-etera, dietil-karbonata, klorbenzena, diklormetana i njihovih smjesa.
The crenolanib or a pharmaceutically acceptable salt thereof may also be provided as a single agent to at least one of post standard induction therapy, or high dose induction therapy, in newly diagnosed proliferative disease. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens u barem jednoj post-standardnoj indukcijskoj terapiji ili indukcijskoj terapiji visoke doze u novodijagnosticiranoj akutnoj mijeloičnoj leukemiji (AML).
In certain embodiments, the present invention is directed to a process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of: 
PATENTNI ZAHTJEVI L Postupak pripreme oralnog farmaceutskog oblika davanja s produljenim otpuštanjem u krutom stanju, koji sadrži barem sljedeće korake:
In an embodiment, the S. pneumoniae infection occurs in the a compartment of the ear, for example the middle ear, for example as an otitis media infection. In an embodiment, the level of Zn2+ and/or Mn2+ in the middle ear is less than 300, 200, 150, 100, 50, 20, 10, 5, 2, 1, 0.5, 0.2 or 0.1 uM. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u srednjem uhu, a koncentracija Mn"* u srednjem uhu je manja od 300, 200, 150, 100, 50, 20, 10, 5, 2, 1, 0,5, 0,2 ili 0,1 uM.
The process according to any one aspects 1 to 3, wherein the binder is in form of a solution or a dry material, preferably in form of an aqueous solution having a binder concentration from 0.5 to 50 wt.-%, preferably from 1 to 40 wt.-%, more preferably from 3 to 20 wt.-%, and most preferably from 4 to 10 wt.-%, based on the total weight of the solution. 
Postupak prema bilo kojem od zahtjeva 1 do 3, gdje je vezivo u obliku otopine ili suhog materijala, poželjno u obliku vodene otopine s koncentracijom veziva od 0.5 do 50% tež., poželjno od 1 do 40% tež., poželjnije od 3 do 20% tež., i najpoželjnije od 4 do 10% tež., u odnosu na ukupnu težinu otopine.
The alcohols b3) that may be used in the odor-masking agent and as defined above are advantageously, and as nonlimiting examples, chosen from menthol, neomenthol, phenylethyl alcohol, benzyl alcohol, citronellol, dihydromyrcenol, dihydroterpineol, dimetol, ethyllinalool, geraniol, linalool, tetrahydrolinalool, tetrahydromyrcenol, nerol, and the like, and also mixtures of two or more thereof. 
10. Pripravak prema zahtjevu 7, gdje se b3) odabire između mentola, neomentola, feniletil alkohola, benzil alkohola, citronelola, dihidromircenola, dihidroterpineola, dimetola, ethilinalola, geraniola, linalola, tetrahidrolinalola, tetrahidromircenola, nerola, i također smjesa dvaju ili više njih.
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, gdje formulacija matrice s produljenim otpuštanjem nakon što je skladištena na 25°C i 60 % relativne vlažnosti (RH) najmanje 1 mjesec daje stupanj otapanja, kada je mjerenje obavljeno u USP aparatu 1 (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37°C, naznačen time da postotak količine oslobođenog aktivnog agensa u 1,4 i 12 sati otapanja nema odstupanje više od oko 15 % točaka u odnosu na odgovarajući in-vitro stupanj otapanja referentne formulacije prije skladištenja.
Great flexibility is thereby provided, and the suspension element may be adapted as required. 
Time se daje velika prilagodljivost 1 ovjesni se element može adaptirati po zahtjevu.
Further, said document suggests that no heating/boiling process takes place prior to the cutting. 
Nadalje, navedeni dokument sugerira da se postupak zagrijavanja/vrenja ne koristi prije rezanja.
Preparations 4 to 6 The following azides were prepared similarly to Preparation 3 from appropriate starting materials:- 
Slijedeći azidi napravljeni su na sličan način s Preparatom 1, iz odgovarajućih polaznih materijala:
is an amino acid residue, which peptide of formula (VIa) or (VIb) is covalently linked to a carrier protein consisting of.a CRM197 protein. 
je aminokiselinski ostatak, te je peptid s formulom (VIa) ili (VIb) kovalentno vezan na protein nosač koji sadrži CRM197 protein.
In this preferred embodiment, the matrices are dispersed in one another in succession together with the active ingredient, thus bringing about the formation of a homogeneous structure responsible for the site-specificity of release. 
U ovom poželjnom vidu kalupi su raspršeni jedan unutar drugog zajedno sa aktivnim sastojkom čime je dobivena homogena struktura odgovorna za mjesno specifično oslobađanje aktivnog sastojka.
Combined organic extracts were dried over Na2SO4 and concentrated to give compound 8b. 
Pomiješane organske ekstrakte osuši se preko Na»SOx, te koncentrira kako bi se dobilo spoj 8b.
moulding the mixture to form lozenges. 
(c) kalupljenje smjese da bi se formirale tablete-pastile.
The use according to any one of claims 18 to 29, wherein the pharmaceutical composition further comprises a hypolipemiant agent, preferably simvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, eptastatin, lifibrol, acifran, acitemate, glunicate or rosuvastatin. 
Upotreba prema bilo kojem zahtjevu 18 do 29, naznačena time, da farmaceutski sastav nadalje sadrži hipolipemijantno sredstvo, ponajprije simvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, eptastatin, lifibrol, acifran, acitemat, glunikat ili rosuvastatin.
The system of claim 1 or 2, providing energy efficiency analysis through automated analysis in real-time and generating an account of electrical energy consumption. 
Sustav prema zahtjevu 1 ili 2, koji automatski generira analizu učinkovitosti električne energije u stvarnom vremenu te obračun potrošnje električne energije.
Use of a compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament in the treatment or prevention of pain or diarrhea. 
Uporaba spoja prema zahtjevu I ili 2 ili njegove farmaceutski prihvatljive soli naznačena time da je za dobivanje lijeka za liječenje ili sprečavanje boli ili proljeva.
a light source; and a phototherapeutic device member having a flexible fiber optic tip member having a core for transmitting light, the flexible tip member including a proximal end and a distal end, wherein the diameter of the proximal end is greater than the diameter of the distal end, and wherein the proximal end is curved to cause light entering the flexible tip member through the proximal end to converge; and 
vršni element fleksibilnog optičkog vlakna koji ima jezgru za prijenos svjetla, gdje fleksibilni vršni element uključuje bliski kraj i udaljeni kraj, gdje je promjer bliskog kraja veći od promjera udaljenog kraja, te gdje bliski kraj je zakrivljen kako bi uzrokovao sabiranje svjetla koje ulazi u fleksibilni vršni element kroz bliski kraj; i elastični cjevasti spojni tuljac, za mehaničko povezivanje fleksibilnog vršnog elementa s izvorom svjetla, gdje tuljac uključuje bliski kraj koji ima otvor i udaljeni kraj koji ima otvor, gdje je bliski kraj konfiguriran da se raširi i mehanički poveže s izvorom svjetla;
Use of Claim 82, wherein the IL-17 antagonist binds to and inhibits the activity of IL- 17, IL-17RA or IL-17RC. 
Uporaba u skladu sa zahtjevom 82, naznačena time, da se IL-17 antagonist veže na i inhibira djelovanje IL-17, IL-17RA ili IL-17RC.